Buscopan Dosage for Abdominal Pain
For adults, the recommended dosage of Buscopan (hyoscine butylbromide) is 10 mg three times daily orally for continuous treatment, or 10-20 mg on-demand (up to 100 mg/day) for acute cramping abdominal pain, with the option to repeat doses every 30 minutes as needed up to 4 additional doses.
Adult Dosing
Continuous Treatment (Recurrent Cramping Pain)
- Standard dose: 10 mg orally three times daily (30 mg/day total) 1, 2
- Duration: Effective when used continuously for up to 3 weeks 1
- This regimen demonstrated statistically significant reduction in pain intensity (2.3 cm on Visual Analogue Scale) compared to placebo (1.9 cm, p<0.0001) 1
On-Demand Treatment (Acute Episodes)
- Initial dose: 10-20 mg orally at onset of cramping pain 3
- Maximum daily dose: 100 mg/day 3
- Repeat dosing: Up to 4 additional doses can be taken every 30 minutes if pain persists 3
- Patients achieved clinically relevant pain reduction (≥2 points on 11-point scale, approximately 30% pain relief) within 45 minutes versus 60 minutes with placebo 3
Pediatric Dosing
For children aged 8-17 years: 10 mg orally as a single dose 4
The 2020 randomized controlled trial in children with nonspecific colicky abdominal pain demonstrated that 10 mg oral hyoscine butylbromide resulted in mean pain scores of 29 mm on a 100 mm visual analogue scale at 80 minutes, with 55% of patients achieving pain scores <30 mm 4. While this study showed hyoscine butylbromide was not superior to acetaminophen, both agents produced clinically important pain reduction and either can be considered appropriate 4.
Clinical Context and Efficacy
When to Use Buscopan
The medication is most effective for:
- Cramping/colicky abdominal pain associated with functional gastrointestinal disorders 3, 1
- Irritable bowel syndrome (IBS): 81% of patients showed marked or some improvement in symptoms with the combination of hyoscine butylbromide plus paracetamol, and 76% with hyoscine butylbromide alone versus 64% with placebo 2
- Recurrent functional abdominal pain where antispasmodic effect is desired 5
Important Caveats
A critical 2024 study found that intravenous hyoscine butylbromide (20 mg) showed NO significant difference compared to placebo for acute gastroenteritis-related cramping pain in the emergency department 6. This suggests that Buscopan may be less effective for inflammatory causes of abdominal pain compared to functional cramping pain.
The mechanism of action involves anticholinergic blockade of muscarinic receptors in the gastrointestinal tract, reducing smooth muscle spasm 5. However, this peripheral action means it works best when pain is driven by smooth muscle spasm rather than inflammation or other pathophysiologic processes.
Safety Profile
- Well tolerated: Adverse events occurred in only 16% of patients on hyoscine butylbromide versus 11% on placebo 1
- No serious adverse effects reported in pediatric trials 4
- Contraindications include narrow-angle glaucoma, myasthenia gravis, megacolon, and obstructive uropathy (standard anticholinergic precautions)
Practical Algorithm
Identify pain type: Cramping/colicky pain suggests Buscopan may be effective; inflammatory pain (like acute gastroenteritis) may not respond 6
Choose regimen based on pattern:
- Recurrent/chronic cramping: 10 mg TID continuously for up to 3 weeks
- Intermittent acute episodes: 10-20 mg on-demand, repeat q30min PRN (max 100 mg/day)
Assess response: Expect pain reduction within 45-60 minutes for on-demand use 3
Consider alternatives if ineffective: The lack of efficacy in acute gastroenteritis 6 suggests that if pain doesn't respond within 60-80 minutes, the underlying cause may not be amenable to antispasmodic therapy
Note: The FDA drug label information provided 7 appears to be for buspirone (an anxiolytic), not Buscopan (hyoscine butylbromide), and should be disregarded for this indication.